We are live on ! Find out more
TCM

TCG Crossover Management Portfolio holdings

AUM $3.5B
1-Year Est. Return 1,165.83%
This Fund
S&P 500
This Quarter Est. Return
+22.55%
1 Year Est. Return
+1,165.83%
3 Year Est. Return
+3,168.76%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$679M
AUM Growth
+$69.3M
Cap. Flow
+$84.1M
Cap. Flow %
12.38%
Top 10 Hldgs %
61.79%
Holding
30
New
8
Increased
3
Reduced
2
Closed
4

Top Buys

Rank Stock Value
1
GPCR icon
Structure Therapeutics
GPCR
+$37.1M
2
INBX
Inhibrx, Inc. Common Stock
INBX
+$36.6M
3
SVRA icon
Savara
SVRA
+$35.7M
4
CMPS
Compass Pathways
CMPS
+$34.2M
5
TSHA icon
Taysha Gene Therapies
TSHA
+$20.8M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$96.3M
2
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$52.9M
3
IMVT icon
Immunovant
IMVT
+$7.23M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$5.49M
5
ALPN
Alpine Immune Sciences Inc
ALPN
+$2.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CCCC icon
26
C4 Therapeutics
CCCC
$397M
$2.37M 0.35%
1,276,574
– –
ACRS icon
27
Aclaris Therapeutics
ACRS
$750M
– –
-529,839
Closed -$5.49M
ALPN
28
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-253,069
Closed -$2.6M
ISEE
29
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-2,448,829
Closed -$96.3M
VECT
30
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
– –
-3,113,600
Closed -$52.9M
1
2

Similar funds

DILIC
Dai-ichi Life Insurance Company Tokyo, Japan $3.49B AUM 27.28% 1-Year Est. Return
KCM
Kedalion Capital Management London, United Kingdom $3.48B AUM 17.74% 1-Year Est. Return
ACM
Aquatic Capital Management Chicago, Illinois $3.48B AUM 24.9% 1-Year Est. Return
BCP
BDT Capital Partners Chicago, Illinois $3.51B AUM 31.02% 1-Year Est. Return
ACA
Anchor Capital Advisors Boston, Massachusetts $3.51B AUM 16.99% 1-Year Est. Return
MSC
MUFG Securities (Canada) New York $3.48B AUM 45.13% 1-Year Est. Return
TH
TCTC Holdings Dallas, Texas $3.51B AUM 30.71% 1-Year Est. Return
PMG
Private Management Group Irvine, California $3.47B AUM 13.39% 1-Year Est. Return

TCG Crossover Management's Q3 2023 Portfolio in Review

As of Q3 2023, TCG Crossover Management held 30 positions worth $679M, up 11% from $610M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

TCG Crossover Management deployed $84.1M of net new capital in Q3 2023, opening 8 new positions and adding to 3 existing holdings. Its largest new stake was Inhibrx, Inc. Common Stock: 1,750,387 shares worth $32.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Immunovant, an estimated $7.23M trimmed.

  • TCG Crossover Management's largest Q3 2023 buy was Inhibrx, Inc. Common Stock: 1,750,387 shares worth $32.1M.
  • TCG Crossover Management added most to Structure Therapeutics in Q3 2023, an estimated $37.1M increase.
  • TCG Crossover Management's biggest Q3 2023 reduction was Immunovant, cutting an estimated $7.23M.
  • TCG Crossover Management fully exited IVERIC bio, Inc. Common Stock in Q3 2023, selling an estimated $96.3M.
  • TCG Crossover Management's ten largest holdings make up 62% of its $679M portfolio in Q3 2023.
  • TCG Crossover Management opened 8 new positions and closed 4 in Q3 2023.
  • TCG Crossover Management's portfolio value rose 11% quarter-over-quarter to $679M.

Based on TCG Crossover Management's 13F filing for Q3 2023, filed 14 Nov 2023.